~~<i id='5250D3D6FF'><strike id='5250D3D6FF'><tt id='5250D3D6FF'><pre id='5250D3D6FF'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：knowledge 2025-09-27 12:56:35 - browse：459

Damian Garde of STAT talks with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho at STAT in NYC. — Damian Garde of STAT, left, talked with Liisa Bayko of Evercore ISI and Jared Holz of Mizuho about the GLP-1 weight loss market. Michelle C. Gevint for STAT

NEW YORK — Will the world actually soon spend $100 billion a year on the new obesity medicines?

Plenty of people in pharma and at the banks that invest in it seem to think so. Goldman Sachs, Barclays, BMO Capital Markets and Pfizer have all arrived at the glossy, cut-for-headline number for spending by around 2030.

Yet Jared Holz, a healthcare strategist at Mizuho, is skeptical.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Gut bacteria may contribute to kidney autoimmunity, study finds

focus

knowledge

focus

leisure time

knowledge

explore

Inanewstudyofmultiplesclerosis,patientsinoneparticularsubgrouphaddifferencesinnaturalkillercells,whi

WSS

Hundreds died while taking an arthritis drug, but nobody alerted patients

Scientific mystery highlights the blind spots in genomics databases

GSK’s asthma push continues as drug succeeds in Phase 3 trials

BIO to announce reorganization, senior leaders expected to depart

Medicare Advantage 2025 payments will dip, Biden administration says

Brain MRIs reveal impact of 'toxic stress' on Black children

focus

explore

focus

Medical records are filled with copy

Bird flu reported in person exposed to presumably infected cattle

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Lawmakers grill UnitedHealth CEO on Change cyberattack

Sports medicine is finally prioritizing gender equality

How a small hospital in rural Puerto Rico survived Hurricane Maria

Walensky prepares to leave CDC — and Congress — behind

U.K. decision on ALS drug has neurologists, advocates up in arms

Medical records are filled with copy

UnitedHealth, in a surprise, takes aim at Steward’s physician group

knowledge

Young boy dies in trial for Pfizer Duchenne gene therapy

Drug companies' payments and gifts affect physicians' prescribing

Young boy dies in trial for Pfizer Duchenne gene therapy

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

The effects of a landmark ruling on DNA ownership are becoming clearer

Alzheimer's risk factor APOE4 may be a distinct form of the disease

focus

leisure time

knowledge

explore